Management

Niklas Prager has extensive and solid experience from the global pharma industry and has held leadership positions in research-focused pharmaceutical companies such as Merck/MSD and Pfizer, with both Sweden and the USA as a base. He has also been CEO and board member/chairperson of several medtech and biotech companies such as Medivir AB and CellaVision AB, and has experience with different types of ownership, from listed to private and private equity.

A trained Neuroscientist, Nina’s career quickly centered on the Cell and Gene Therapy space, holding various technical and commercial roles at the Scottish Center for Regenerative Medicine (Edinburgh, UK) and the Cell and Gene Therapy Catapult (London, UK). She deepened her global commercial experience establishing Lonza’s autologous Cell Therapy Business and strategic positioning by incorporating the Cocoon™ technology with a vision for near-patient manufacturing (Basel, CH), as well as leading commercial teams at MilliporeSigma/Merck KGaA (Boston, USA) focusing on the Cell Therapy product portfolio, Gene Therapy manufacturing services and CRISPR IP licensing. Aside from large corporate and public sector leadership roles, Nina established her start-up and C-suite acumen as the Chief Commercial Officer for FloDesign Sonics (Wilbraham, USA), leading to the company’s acquisition by MilliporeSigma, as well as a wide range of advisory board engagements.

• CEO and COO Bactiguard ​
• Business Sweden in Japan ​
• Investment Banking at SEB ​
• McKinsey and Bain​
• M. Sc. In Business and Economics from Stockholm School of Economics.

Staffan is one of the Founders of SmartCella and Professor in Clinical Neuroimaging in the department of Clinical Neuroscience, Karolinska Institutet and Senior physician/Consultant in endovascular neurointerventional procedures in the department of Neuroradiology, Karolinska University Hospital, as well as research group leader who has published widely on novel neuroimaging and interventional techniques. In 2016, he gave the Seldinger Honorary Lecture at the European Congress of Radiology. In 2020, he received the Hans Wigzell Foundation Science Prize.​

• Medical degree cardiology at Harvard Medical
• Internal Medicine at NYPH-Weil Cornell Cardiology
• Fellowship at Massachusetts General Hospital
• Research work at Karolinska Institutet focused on novel cardiac stem cell and RNA therapies for heart disease.

• PhD in Neuroscience Karolinska Institutet
• Fellow at Columbia University (New York) diabetes and stem cells.
• Research at Karolinska Institutet aimed to translate cardiac stem cell therapy for treatment of heart disease.

• MSc Business and Economics Stockholm School of Economics & HEC Paris (Accounting & Finance). ​
• Formerly: Morgan Stanley Healthcare, Altor Private Equity, Novo Holdings, Impilo Private Equity

Ann Fredriksson has extensive experience of senior HR and management positions from fast growing international businesses within Medtech, Biotech, IT and Software, companies such as Vironova AB and Jeeves Information Systems AB. She is a business-oriented HR professional with a sales & marketing background and has broad experience of working with organizations in change. Ann has held leadership positions at a strategic and operational level for more than 20 years and her competence covers the entire HR area with an emphasis on development and change management.